CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
ASP Isotopes›
Library
ASP Isotopes

ASP Isotopes

ASP Isotopes enriches stable isotopes for medical, semiconductor, and nuclear energy customers with Aerodynamic Separation Process and Quantum Enrichment technologies.

Operating headquarters
Dallas, TX, US🇺🇸
Founded
2021
Loading
Overview
Relationships
Analysis
Compare
Employees
News
Library

ASP Isotopes - Library

Official pages and third-party coverage in one index.

aspisotopes.com·16 items across 10 mapped pages · Crawled Sep 29, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

3 pages
  1. Medical/medical

    We specialize in the production of stable isotopes that are at the forefront of technological advances in the nuclear medicine sector.

  2. Semiconductors/semiconductors

    We are aiming to establish ourselves as an indispensable part of the semiconductor supply chain.

  3. Technology/technology

    ASP Isotopes has its origins in the South African Uranium Enrichment Program of the 1980s. We utilize two proprietary technologies for the enrichment of

Team

1 page
  1. People/people

    People People LEADERSHIP Paul E. Mann​Chairman of the Board, Chief Executive Officer Paul Mann co-founded ASP Isotopes in September 2021 and serves as the

About

1 page
  1. Our Company/our-company

    ASP Isotopes Inc. was incorporated in 2021 though its origins date back to South Africa’s uranium enrichment program in the 1980s. The company is comprised of

Contact

1 page
  1. Contact/contact

    Stay informed with periodic updates on important company developments.

Homepage

1 page
  1. Homepage/

    Isotopes are two or more atoms of the same chemical element with the same number of protons and electrons but slightly different numbers of neutrons.

Privacy

2 pages
  1. Cookie Notice/cookie-notice

    ASP Isotopes Inc.’s website does not automatically collect personally identifiable information. We do track certain information about the visits to our

  2. Privacy Policy/privacy-policy

    ASP Isotopes Inc. does not disclose, give, sell or transfer any personal information about our visitors, unless required by law enforcement or by statute.

Terms & Conditions

1 page
  1. Terms and Conditions/terms-and-conditions

    This site and all of its contents, including all text and images (collectively “Content”) are owned or licensed by ASP Isotopes Inc. All rights are reserved

Not yet classified

1 page
  1. aspisotopes.com/

    Isotopes are two or more atoms of the same chemical element with the same number of protons and electrons but slightly different numbers of neutrons.

Coverage

5 items
  1. ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Updatemarkets.businessinsider.com/news/stocks/asp-isotopes-hosts-inaugural-capital-markets-day-and-provides-operational-update-1036528480

    ASP Isotopes Inc. hosts its inaugural Capital Markets Day in London and provides an operational update across its businesses. Management outlines the company's strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels.

    Sep 2026 · Markets InsiderNews article

  2. Texas A&M welcomes uranium conversion researchans.org/news/2026-07-22/article-8234/texas-am-welcomes-uranium-conversion-research/

    The Texas A&M Engineering Experiment Station (TEES) signs a research agreement with Quantum Leap Energy (QLE) to advance and de-risk commercial production of high-purity uranium hexafluoride (UF6). The partnership’s stated objective combines progress toward commercial production with efforts to reduce risks in that production process.

    Jul 2026 · ANS Nuclear NewswireNews article

  3. ASP Isotopes Soars On Restart Of Silicon-28 Facility, Locks In Q3 2026 Commercial Shipmentszerohedge.com/markets/asp-isotopes-restarts-silicon-28-facility-locks-q3-2026-commercial-shipments

    ASP Isotopes restarts its Silicon-28 facility and locks in commercial shipments for Q3 2026. The company is also making progress across silicon, helium, and uranium.

    May 2026 · ZeroHedgeNews article

  4. ASP Isotopes Completes Well Drilling Required for Phase 1 of Renergen Helium Project Four Months Ahead of Scheduleredchip.com/news/5207340210622453/asp-isotopes-completes-well-drilling-required-for-phase1-of-renergen-helium-project-four-months-ahead-of-schedule

    ASP Isotopes says it has completed drilling the wells required for Phase 1 of the Renergen Helium Project approximately four months ahead of schedule. The advanced materials company develops technologies and processes for producing critical materials used in multiple industries.

    Mar 2026 · GlobeNewswire (via RedChip.com)News article